Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to extend the Pre-Crest study (Protocol # (NCT00592995)
to further assess the long-term safety and tolerability of up to 30 grams daily creatine in
individuals at-risk for Huntington's Disease (HD) and to assess whether biomarkers responsive
to creatine in symptomatic individuals are informative in premanifest individuals over a
longer duration.